AN2 Therapeutics, Inc.
ANTX
$5.64
-$0.34-5.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -24.24% | 56.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.61% | 13.26% | |||
| Operating Income | 15.61% | -13.26% | |||
| Income Before Tax | 18.38% | -15.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.38% | -15.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.38% | -15.13% | |||
| EBIT | 15.61% | -13.26% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 37.87% | -2.61% | |||
| Normalized Basic EPS | 37.88% | -2.62% | |||
| EPS Diluted | 37.87% | -2.61% | |||
| Normalized Diluted EPS | 37.88% | -2.62% | |||
| Average Basic Shares Outstanding | 31.42% | 12.20% | |||
| Average Diluted Shares Outstanding | 31.42% | 12.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||